Novel immune signals and atherosclerosis

Current Atherosclerosis Reports

Volumn 14, Issue 5, 2012, Pages 484-490

  Iwata, Hiroshi ^a,c   Nagai, Ryozo ^b,c  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b JICHI MEDICAL UNIVERSITY   (Japan)

^c UNIVERSITY OF TOKYO   (Japan)

Author keywords

Immune response; Inflammation in atherosclerosis; Macrophages; Molecular mechanism; Monocytes

Indexed keywords

CHEMOKINE; COLONY STIMULATING FACTOR 1; CYTOKINE; ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 8; MONOCYTE CHEMOTACTIC PROTEIN 1; NUCLEOTIDE BINDING OLIGOMERIZATION DOMAIN LIKE RECEPTOR; PADGEM PROTEIN; REACTIVE OXYGEN METABOLITE; RETINOIC ACID INDUCIBLE PROTEIN I; TOLL LIKE RECEPTOR; TRANSFORMING GROWTH FACTOR BETA; VASCULAR CELL ADHESION MOLECULE 1;

ADAPTIVE IMMUNITY; ATHEROGENESIS; ATHEROSCLEROSIS; CELL HETEROGENEITY; CELL POLARITY; CELLULAR IMMUNITY; CHRONIC INFLAMMATION; CYTOKINE PRODUCTION; CYTOLOGY; HUMAN; IMMUNOREGULATION; INNATE IMMUNITY; MACROPHAGE; MOLECULAR MECHANICS; MONOCYTE; NONHUMAN; REVIEW; SIGNAL TRANSDUCTION; TH1 CELL;

ANIMALS; ATHEROSCLEROSIS; CORONARY ARTERY DISEASE; HUMANS; MACROPHAGES; MONOCYTES; RISK FACTORS; SIGNAL TRANSDUCTION;

EID: 84870533039     PISSN: 15233804     EISSN: 15346242     Source Type: Journal    
DOI: 10.1007/s11883-012-0267-7     Document Type: Review

References (70)

1. Ross R, Glomset JA. Atherosclerosis and the arterial smooth muscle cell: proliferation of smooth muscle is a key event in the genesis of the lesions of atherosclerosis. Science. 1973;180:1332-9.
2. Blake GJ, Ridker PM. Novel clinical markers of vascular wall inflammation. Circ Res. 2001;89:763-71.
3. Kaptoge S, Di Angelantonio E, Lowe G, Pepys MB, Thompson SG, Collins R, et al. C-reactive protein concentration and risk of coronary heart disease, stroke, and mortality: an individual participant meta-analysis. Lancet. 2010;375:132-40.
4. Ridker PM. The time for cardiovascular inflammation reduction trials has arrived: how low to go for hscrp? Arterioscler Thromb Vasc Biol. 2008;28:1222-4.
5. Rubin J, Chang HJ, Nasir K, Blumenthal RS, Blaha MJ, Choi EK, et al. Association between high-sensitivity c-reactive protein and coronary plaque subtypes assessed by 64-slice coronary computed tomography angiography in an asymptomatic population. Circ Cardiovasc Imaging. 2011;4:201-9.
6. Ridker PM, Danielson E, Fonseca FA, Genest J, Gotto Jr AM, Kastelein JJ, et al. Rosuvastatin to prevent vascular events in men and women with elevated c-reactive protein. N Engl J Med. 2008;359:2195-207.
7. Tacke F, Alvarez D, Kaplan TJ, Jakubzick C, Spanbroek R, Llodra J, et al. Monocyte subsets differentially employ ccr2, ccr5, and cx3cr1 to accumulate within atherosclerotic plaques. J Clin Invest. 2007;117:185-94.
8. Tedgui A, Mallat Z. Cytokines in atherosclerosis: pathogenic and regulatory pathways. Physiol Rev. 2006;86:515-81.
9. Hansson GK, Hermansson A. The immune system in atherosclerosis. Nat Immunol. 2011;12:204-12.
10. Yvan-Charvet L, Ranalletta M, Wang N, Han S, Terasaka N, Li R, et al. Combined deficiency of abca1 and abcg1 promotes foam cell accumulation and accelerates atherosclerosis in mice. J Clin Invest. 2007;117:3900-8.
11. Glass CK, Witztum JL. Atherosclerosis. The road ahead. Cell. 2001;104:503-16.
12. Tabas I. Macrophage death and defective inflammation resolution in atherosclerosis. Nat Rev Immunol. 2010;10:36-46.
13. Hansson GK, Robertson AK, Soderberg-Naucler C. Inflammation and atherosclerosis. Annu Rev Pathol. 2006;1:297-329.
14. Tabas I, Williams KJ, Boren J. Subendothelial lipoprotein retention as the initiating process in atherosclerosis: update and therapeutic implications. Circulation. 2007;116:1832-44.
15. Eriksson EE, Xie X, Werr J, Thoren P, Lindbom L. Importance of primary capture and l-selectin-dependent secondary capture in leukocyte accumulation in inflammation and atherosclerosis in vivo. J Exp Med. 2001;194:205-18.
16. Nakashima Y, Raines EW, Plump AS, Breslow JL, Ross R. Upregulation of vcam-1 and icam-1 at atherosclerosis-prone sites on the endothelium in the apoe-deficient mouse. Arterioscler Thromb Vasc Biol. 1998;18:842-51.
17. Dje N'Guessan P, Riediger F, Vardarova K, Scharf S, Eitel J, Opitz B, et al. Statins control oxidized ldl-mediated histone modifications and gene expression in cultured human endothelial cells. Arterioscler Thromb Vasc Biol. 2009;29:380-6.
18. Smith JD, Trogan E, Ginsberg M, Grigaux C, Tian J, Miyata M. Decreased atherosclerosis in mice deficient in both macrophage colony-stimulating factor (op) and apolipoprotein e. Proc Natl Acad Sci USA. 1995;92:8264-8.
19. Bianchi ME. Damps, pamps and alarmins: all we need to know about danger. J Leukoc Biol. 2007;81:1-5.
20. Takeuchi O, Akira S. Pattern recognition receptors and inflammation. Cell. 2010;140:805-20.
21. Cole JE, Mitra AT, Monaco C. Treating atherosclerosis: the potential of toll-like receptors as therapeutic targets. Expert Rev Cardiovasc Ther. 2010;8:1619-35.
22. Kawai T, Akira S. The role of pattern-recognition receptors in innate immunity: update on toll-like receptors. Nat Immunol. 2010;11:373-84.
23. Seneviratne AN, Sivagurunathan B, Monaco C. Toll-like receptors and macrophage activation in atherosclerosis. Clin Chim Acta. 2012;413:3-14.
24. Cole JE, Georgiou E, Monaco C. The expression and functions of toll-like receptors in atherosclerosis. Mediators Inflamm. 2010;2010:393946.
25. Stemme S, Faber B, Holm J, Wiklund O, Witztum JL, Hansson GK. T lymphocytes from human atherosclerotic plaques recognize oxidized low density lipoprotein. Proc Natl Acad Sci USA. 1995;92:3893-7.
26. Bourke E, Bosisio D, Golay J, Polentarutti N, Mantovani A. The toll-like receptor repertoire of human b lymphocytes: inducible and selective expression of tlr9 and tlr10 in normal and transformed cells. Blood. 2003;102:956-63.
27. Hornung V, Rothenfusser S, Britsch S, Krug A, Jahrsdorfer B, Giese T, et al. Quantitative expression of toll-like receptor 1-10 mrna in cellular subsets of human peripheral blood mononuclear cells and sensitivity to cpg oligodeoxynucleotides. J Immunol. 2002;168:4531-7.
28. Mansson A, Adner M, Hockerfelt U, Cardell LO. A distinct toll-like receptor repertoire in human tonsillar b cells, directly activated by pamcsk, r-837 and cpg-2006 stimulation. Immunology. 2006;118:539-48.
29. Wagner M, Poeck H, Jahrsdoerfer B, Rothenfusser S, Prell D, Bohle B, et al. Il-12p70-dependent th1 induction by human b cells requires combined activation with cd40 ligand and cpg DNA. J Immunol. 2004;172:954-63.
30. Lee JG, Lim EJ, Park DW, Lee SH, Kim JR, Baek SH. A combination of lox-1 and nox1 regulates tlr9-mediated foam cell formation. Cell Signal. 2008;20:2266-75.
31. Doyle SE, O'Connell RM, Miranda GA, Vaidya SA, Chow EK, Liu PT, et al. Toll-like receptors induce a phagocytic gene program through p38. J Exp Med. 2004;199:81-90.
32. Hoebe K, Georgel P, Rutschmann S, Du X, Mudd S, Crozat K, et al. Cd36 is a sensor of diacylglycerides. Nature. 2005;433:523-7.
33. Triantafilou M, Gamper FG, Haston RM, Mouratis MA, Morath S, Hartung T, et al. Membrane sorting of toll-like receptor (tlr)-2/6 and tlr2/1 heterodimers at the cell surface determines heterotypic associations with cd36 and intracellular targeting. J Biol Chem. 2006;281:31002-11.
34. Jeannin P, Bottazzi B, Sironi M, Doni A, Rusnati M, Presta M, et al. Complexity and complementarity of outer membrane protein a recognition by cellular and humoral innate immunity receptors. Immunity. 2005;22:551-60.
35. Elhage R, Jawien J, Rudling M, Ljunggren HG, Takeda K, Akira S, et al. Reduced atherosclerosis in interleukin-18 deficient apolipoprotein e-knockout mice. Cardiovasc Res. 2003;59:234-40.
36. Gerdes N, Sukhova GK, Libby P, Reynolds RS, Young JL, Schonbeck U. Expression of interleukin (il)-18 and functional il-18 receptor on human vascular endothelial cells, smooth muscle cells, and macrophages: implications for atherogenesis. J Exp Med. 2002;195:245-57.
37. Kirii H, Niwa T, Yamada Y, Wada H, Saito K, Iwakura Y, et al. Lack of interleukin-1beta decreases the severity of atherosclerosis in apoe-deficient mice. Arterioscler Thromb Vasc Biol. 2003;23:656-60.
38. Foks AC, Frodermann V, ter Borg M, Habets KL, Bot I, Zhao Y, et al. Differential effects of regulatory t cells on the initiation and regression of atherosclerosis. Atherosclerosis. 2011;218:53-60.
39. Gotsman I, Grabie N, Gupta R, Dacosta R, MacConmara M, Lederer J, et al. Impaired regulatory t-cell response and enhanced atherosclerosis in the absence of inducible costimulatory molecule. Circulation. 2006;114:2047-55.
40. Steinman RM, Banchereau J. Taking dendritic cells into medicine. Nature. 2007;449:419-26.
41. Hansson GK. Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med. 2005;352:1685-95.
42. Stoger JL, Goossens P, deWinther MP. Macrophage heterogeneity: relevance and functional implications in atherosclerosis. Curr Vasc Pharmacol. 2010;8:233-48.
43. Geissmann F, Jung S, Littman DR. Blood monocytes consist of two principal subsets with distinct migratory properties. Immunity. 2003;19:71-82.
44. Swirski FK, Libby P, Aikawa E, Alcaide P, Luscinskas FW, Weissleder R, et al. Ly-6chi monocytes dominate hypercholesterolemia-associated monocytosis and give rise to macrophages in atheromata. J Clin Invest. 2007;117:195-205.
45. Nahrendorf M, Swirski FK, Aikawa E, Stangenberg L, Wurdinger T, Figueiredo JL, et al. The healing myocardium sequentially mobilizes two monocyte subsets with divergent and complementary functions. J Exp Med. 2007;204:3037-47.
46. Boring L, Gosling J, Cleary M, Charo IF. Decreased lesion formation in ccr2-/- mice reveals a role for chemokines in the initiation of atherosclerosis. Nature. 1998;394:894-7.
47. Auffray C, Sieweke MH, Geissmann F. Blood monocytes: development, heterogeneity, and relationship with dendritic cells. Annu Rev Immunol. 2009;27:669-92.
48. Gordon S, Taylor PR. Monocyte and macrophage heterogeneity. Nat Rev Immunol. 2005;5:953-64.
49. Rothe G, Gabriel H, Kovacs E, Klucken J, Stohr J, Kindermann W, et al. Peripheral blood mononuclear phagocyte subpopulations as cellular markers in hypercholesterolemia. Arterioscler Thromb Vasc Biol. 1996;16:1437-47.
50. Tsujioka H, Imanishi T, Ikejima H, Kuroi A, Takarada S, Tanimoto T, et al. Impact of heterogeneity of human peripheral blood monocyte subsets on myocardial salvage in patients with primary acute myocardial infarction. J Am Coll Cardiol. 2009;54:130-8.
51. Wildgruber M, Lee H, Chudnovskiy A, Yoon TJ, Etzrodt M, Pittet MJ, et al. Monocyte subset dynamics in human atherosclerosis can be profiled with magnetic nano-sensors. PLoS One. 2009;4:e5663.
52. Remy-Martin JP, Marandin A, Challier B, Bernard G, Deschaseaux M, Herve P, et al. Vascular smooth muscle differentiation of murine stroma: a sequential model. Exp Hematol. 1999;27:1782-95.
53. Sata M, Saiura A, Kunisato A, Tojo A, Okada S, Tokuhisa T, et al. Hematopoietic stem cells differentiate into vascular cells that participate in the pathogenesis of atherosclerosis. Nat Med. 2002;8:403-9.
54. Simper D, Stalboerger PG, Panetta CJ, Wang S, Caplice NM. Smooth muscle progenitor cells in human blood. Circulation. 2002;106:1199-204.
55. Iwata H, Manabe I, Fujiu K, Yamamoto T, Takeda N, Eguchi K, et al. Bone marrow-derived cells contribute to vascular inflammation but do not differentiate into smooth muscle cell lineages. Circulation. 2010;122:2048-57.
56. Bellini A, Mattoli S. The role of the fibrocyte, a bone marrowderived mesenchymal progenitor, in reactive and reparative fibroses. Lab Invest. 2007;87:858-70.
57. Greaves DR, Gordon S. The macrophage scavenger receptor at 30 years of age: current knowledge and future challenges. J Lipid Res. 2009;50(Suppl):S282- 6.
58. Martinez FO, Gordon S, Locati M, Mantovani A. Transcriptional profiling of the human monocyte-to-macrophage differentiation and polarization: new molecules and patterns of gene expression. J Immunol. 2006;177:7303-11.
59. Kadl A, Meher AK, Sharma PR, Lee MY, Doran AC, Johnstone SR, et al. Identification of a novel macrophage phenotype that develops in response to atherogenic phospholipids via nrf2. Circ Res. 2010;107:737-46.
60. Shalhoub J, Falck-Hansen MA, Davies AH, Monaco C. Innate immunity and monocyte-macrophage activation in atherosclerosis. J Inflamm (Lond). 2011;8:9.
61. Boyle JJ, Johns M, Kampfer T, Nguyen AT, Game L, Schaer DJ, et al. Activating transcription factor 1 directs mhem atheroprotective macrophages through coordinated iron handling and foam cell protection. Circ Res. 2012;110:20-33.
62. Butcher MJ, Galkina EV. Phenotypic and functional heterogeneity of macrophages and dendritic cell subsets in the healthy and atherosclerosis-prone aorta. Front Physiol. 2012;3:44.
63. Gleissner CA. Macrophage phenotype modulation by cxcl4 in atherosclerosis. Front Physiol. 2012;3:1.
64. Kirbis S, Breskvar UD, Sabovic M, Zupan I, Sinkovic A. Inflammation markers in patients with coronary artery disease-comparison of intracoronary and systemic levels.Wien Klin Wochenschr. 2010;122 Suppl 2:31-4.
65. Savchenko A, Imamura M, Ohashi R, Jiang S, Kawasaki T, Hasegawa G, et al. Expression of pentraxin 3 (ptx3) in human atherosclerotic lesions. J Pathol. 2008;215:48-55.
66. Khallou-Laschet J, Varthaman A, Fornasa G, Compain C, Gaston AT, Clement M, et al. Macrophage plasticity in experimental atherosclerosis. PLoS One. 2010;5:e8852.
67. Aliev G, Smith MA, Turmaine M, Neal ML, Zimina TV, Friedland RP, et al. Atherosclerotic lesions are associated with increased immunoreactivity for inducible nitric oxide synthase and endothelin-1 in thoracic aortic intimal cells of hyperlipidemic watanabe rabbits. Exp Mol Pathol. 2001;71:40-54.
68. Mallat Z, Gojova A, Marchiol-Fournigault C, Esposito B, Kamate C, Merval R, et al. Inhibition of transforming growth factor-beta signaling accelerates atherosclerosis and induces an unstable plaque phenotype in mice. Circ Res. 2001;89:930-4.
69. Mosser DM, Edwards JP. Exploring the full spectrum of macrophage activation. Nat Rev Immunol. 2008;8:958-69.
70. Thorp E, Tabas I. Mechanisms and consequences of efferocytosis in advanced atherosclerosis. J Leukoc Biol. 2009;86:1089-95.